Summary
ChrysCapital has acquired a controlling 70.68% stake in Novartis India Limited, marking its first majority investment in India's pharmaceutical sector. The company plans to rename and rebrand, with Vikas Gupta appointed as the new CEO to develop a competitive branded generics platform for the Indian market.